Circulating Tumor Cell Enumeration and Characterization in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Cabazitaxel

(1) Background: Markers identifying which patients with metastatic, castration-resistant prostate cancer (mCRPC) will benefit from cabazitaxel therapy are currently lacking. Therefore, the aim of this study was to identify markers associated with outcome to cabazitaxel therapy based on counts and ge...

Descripción completa

Detalles Bibliográficos
Autores principales: de Kruijff, Ingeborg E., Sieuwerts, Anieta M., Onstenk, Wendy, Kraan, Jaco, Smid, Marcel, Van, Mai N., van der Vlugt-Daane, Michelle, Oomen-de Hoop, Esther, Mathijssen, Ron H.J., Lolkema, Martijn P., de Wit, Ronald, Hamberg, Paul, Meulenbeld, Hielke J., Beeker, Aart, Creemers, Geert-Jan, Martens, John W.M., Sleijfer, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6721462/
https://www.ncbi.nlm.nih.gov/pubmed/31434336
http://dx.doi.org/10.3390/cancers11081212

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6721462/
https://www.ncbi.nlm.nih.gov/pubmed/31434336
http://dx.doi.org/10.3390/cancers11081212

Ejemplares similares